Tendances en longévité

Semaglutide and tirzepatide now in dedicated longevity trials; SELECT trial data fueling debate on mortality/inflammation benefits beyond weight loss.

DunedinPACE, GrimAge, and Horvath clock derivatives now standard readouts in longevity intervention trials; commercial testing exploding.

EVERLAST and PEARL trial results driving mainstream attention; now the most-discussed prescription longevity drug among physicians and biohackers.

Yamanaka factor-based partial reprogramming showing age-reversal in animal models; multiple biotech companies in race to human trials.

Dasatinib plus quercetin and fisetin combinations in active human trials; senescent cell clearance now a mainstream geroscience target.

Explicitly listed in longevity trial registries for slowing biological aging; dual GIP/GLP-1 mechanism sparks unique healthspan interest.

Injectable NR formulations and NMN trials gaining traction; NAD+ decline framed as central to mitochondrial and DNA repair aging.

Empagliflozin and dapagliflozin showing telomere-preserving and mitochondrial benefits; cardiorenal protection reframed as potential geroscience.

Consumer biological age tests from companies like TruDiagnostic and Elysium now mainstream; demand surging for actionable aging biomarkers.

SASP-suppressing compounds like navitoclax and ruxolitinib modulating senescent cell secretome without killing cells; active research frontier.

Mitophagy activator now in clinical trials for muscle endurance; Timeline Longevity product driving consumer awareness of mitochondrial renewal.

TAME trial ongoing; metformin remains the benchmark geroscience drug and reference point for all new longevity compound comparisons.

HBOT protocols showing telomere lengthening and senescent cell reduction in human trials; growing clinic network driving mainstream adoption.

Flavonoid fisetin emerging as accessible OTC senolytic; Mayo Clinic trials ongoing and social media buzz growing around anti-aging potential.

ApoB replacing LDL as the preferred cardiovascular longevity biomarker; Peter Attia and longevity physicians driving widespread adoption.

Therapeutic plasma exchange and heterochronic parabiosis-inspired interventions showing biological age lowering in recent human data.

CGM use expanding beyond diabetics into longevity optimization; real-time glucose data now central to personalized metabolic health protocols.

CD38 identified as major NAD+ consumer in aging; apigenin and kuromanin as natural inhibitors gaining longevity supplement attention.

Klotho as a circulating longevity factor linked to cognitive and kidney aging; FGF23-Klotho axis now a drug target in geroscience.

Chronic low-grade inflammation now a druggable aging target; IL-6 pathway, canakinumab trials, and colchicine longevity data driving interest.

Polyamine spermidine promoting autophagy and showing cardiovascular and cognitive benefits in observational studies; supplement market surging.

TRIIM and THYMO trials showing thymus regrowth and immune rejuvenation; thymic involution now a key immunosenescence target.

MSC infusions for systemic inflammation and tissue regeneration in aging adults; clinical trial activity and longevity clinic offerings accelerating.

Valter Longo's ProLon FMD showing biomarker improvements in multiple trials; cyclic fasting now a standard longevity protocol recommendation.

Gut bacteria Akkermansia now commercially available; linked to metabolic health, longevity biomarkers, and centenarian microbiome signatures.

Bio-liquidity concept driving banking of younger stem cells for future use; companies offering cryopreservation of MSCs and HSCs at peak youth.

Glycine plus NAC combination restoring glutathione and mitochondrial function in older adults; Rajagopal trial data driving clinical adoption.

2023 Science paper showing taurine decline with aging and lifespan extension in multiple species reignited sustained interest in taurine as longevity supplement.

Age-related somatic mutations in blood stem cells linked to cardiovascular disease and cancer; emerging as a major modifiable aging risk factor.

Repurposed dye gaining biohacker and longevity physician interest for mitochondrial electron transport enhancement and neuroprotection.

Blood-based Alzheimer's biomarker enabling early detection; central to longevity medicine's shift toward preclinical neurodegeneration intervention.

TRAVERSE trial data clarifying cardiovascular safety; TRT now integrated into longevity medicine protocols for muscle, metabolic, and cognitive health.

AMPK as a cellular energy sensor and longevity switch; compounds like berberine and PT-1 targeting AMPK gaining geroscience attention.

Broccoli-derived NRF2 activator with consistent data on inflammation and detoxification; longevity clinics adding it to standard supplement stacks.

TA-65 and TERT gene therapy approaches for telomere lengthening; Maria Blasco's work and BioViva gene therapy keeping this frontier alive.

Evolocumab and inclisiran for aggressive LDL/ApoB lowering as cardiovascular longevity strategy; now part of preventive longevity protocols.

IgG glycosylation-based biological age test gaining traction as an inflammation-sensitive aging clock with actionable intervention feedback.

Aging immune system rejuvenation via thymus regeneration, CAR-T approaches, and senolytics; recognized as essential for longevity and cancer defense.

Body protection compound peptide gaining popularity for tissue repair and gut healing; biohacker use expanding despite limited human trial data.

HMOs like 2'-FL now in adult longevity supplements for gut microbiome and immune modulation; Zoe and Pendulum driving consumer awareness.

Biomarker-driven individualized protocols at clinics like Function Health and Fountain Life; precision geroscience now a commercial category.

CLEAR Outcomes trial showing cardiovascular event reduction; oral alternative to statins now entering longevity-focused cardioprotection protocols.

Controlled hypoxia-hyperoxia cycles showing HIF-1α activation, mitochondrial benefits, and cognitive effects; emerging longevity biohacking protocol.

Oral microbiome composition linked to systemic inflammation and cognitive aging; now an emerging biomarker and intervention target in longevity medicine.